Abstract:BackgroundPatient-derived tumor models are the new standard for pre-clinical drug testing and biomarker discovery. However, the emerging technology of primary pancreatic cancer organoids has not yet been broadly implemented in research, and complex organotypic models using organoids in co-culture with stromal and immune cellular components of the tumor have yet to be established. In this study, our objective was to develop and characterize pancreatic cancer organoids and multi-cell type organotypic co-culture models to demonstrate their applicability to the study of pancreatic cancer.MethodsWe employed organoid culture methods and flow cytometric, cytologic, immunofluorescent and immunohistochemical methods to develop and characterize patient-derived pancreatic cancer organoids and multi-cell type organotypic co-culture models of the tumor microenvironment.ResultsWe describe the culture and characterization of human pancreatic cancer organoids from resection, ascites and rapid autopsy sources and the derivation of adherent tumor cell monocultures and tumor-associated fibroblasts from these sources. Primary human organoids displayed tumor-like cellular morphology, tissue architecture and polarity in contrast to cell line spheroids, which formed homogenous, non-lumen forming spheres. Importantly, we demonstrate the construction of complex organotypic models of tumor, stromal and immune components of the tumor microenvironment. Activation of myofibroblast-like cancer associated fibroblasts and tumor-dependent lymphocyte infiltration were observed in these models.ConclusionsThese studies provide the first report of novel and disease-relevant 3D in-vitro models representing pancreatic tumor, stromal and immune components using primary organoid co-cultures representative of the tumor-microenvironment. These models promise to facilitate the study of tumor-stroma and tumor-immune interaction and may be valuable for the assessment of immunotherapeutics such as checkpoint inhibitors in the context of T-cell infiltration.

A combinatorial culture strategy to develop pseudomyxoma peritonei organoid models

Precision oncology and systemic targeted therapy in Pseudomyxoma Peritonei

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens

Decellularized Normal and Tumor Extracellular Matrix as Scaffold for Cancer Organoid Cultures of Colorectal Peritoneal Metastases

Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases

Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma

A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Organoid co-culture models of the tumor microenvironment promote precision medicine

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei

Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing

Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications in a common base culture media system

Progress in Biological Research and Treatment of Pseudomyxoma Peritonei

Organoid Modeling of the Tumor Immune Microenvironment

Patient-derived micro-organospheres enable clinical precision oncology

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

Patient-derived organoids in precision cancer medicine

Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6

Establishment of patient‐derived organotypic tumor spheroid models for tumor microenvironment modeling

Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN